TROPION-Breast01: Datopotamab Deruxtecan Vs Chemotherapy in Pre-Treated Inoperable or Metastatic HR+/HER2-breast Cancer
FUTURE ONCOLOGY(2024)
摘要
Improving the prognosis for patients with metastatic HR+/HER2- breast cancer remains an unmet need. Patients with tumors that have progressed on endocrine therapy and/or are not eligible for endocrine therapy had limited treatment options beyond chemotherapy. Antibody-drug conjugates are a novel and promising treatment class in this setting. Datopotamab deruxtecan (Dato-DXd) consists of a TROP2-directed humanized IgG1 monoclonal antibody attached via a serum-stable cleavable linker to a topoisomerase I inhibitor payload. TROPION-Breast01 is an ongoing phase III study that is evaluating the efficacy and safety of Dato-DXd compared with investigator's choice of standard-of-care chemotherapy in patients with inoperable or metastatic HR+/HER2- breast cancer who have received one or two prior lines of systemic chemotherapy in the inoperable or metastatic setting. Clinical Trial Registration: NCT05104866 ( ClinicalTrials.gov )
更多查看译文
关键词
antibody-drug conjugate (ADC),datopotamab deruxtecan (Dato-DXd),HR-positive,HER2-negative,inoperable breast cancer,metastatic breast cancer,Trophoblast cell surface antigen 2 (TROP2)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要